Keratoacanthoma Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Keratoacanthoma Market Trends and Insights

Aging and Cumulative Ultraviolet Exposure

The keratoacanthoma market reflects the growing number of older people with long-term exposure to ultraviolet radiation. The reported global peak age for keratoacanthoma has shifted to 65 to 71 years, from 50 to 69 years during the 1990s.^{[1]“New Insights Into Pathogenesis and Management of Keratoacanthoma: A Narrative Review,”} Age can weaken nucleotide excision repair, base excision repair, and Langerhans cell surveillance, which leaves repeatedly sun-damaged skin more susceptible to squamoproliferative changes. The World Health Organization reported an 88% increase in deaths from occupational solar ultraviolet exposure-related non-melanoma skin cancer between 2000 and 2019.^{[2]“New Study Results Show UV Radiation Is Responsible for More Than 80% of Melanoma Cases Worldwide,”} Australia, New Zealand, and the United States have particularly high age-standardized non-melanoma skin cancer incidence, which supports sustained demand for assessment and treatment.^{[3]“Burden of Skin Cancer in Older Adults From 1990 to 2021 and Modelled Projections,”} In Southeast Asia and the Middle East, substantial outdoor exposure and historically limited surveillance can lead to a larger visible caseload as diagnostic capacity improves.

Screening, Referral, and Non-Surgical Care Expansion

The keratoacanthoma market benefits when skin-lesion screening and early specialist referral identify lesions before they become more complex to manage. Community dermatologists and trained nurse practitioners can use digital imaging to route patients with suspicious lesions to specialists, which can shorten the time to diagnosis. The same referral model can help patients with multiple, eruptive, or cosmetically sensitive lesions access care that does not rely solely on excision. Intralesional methotrexate has produced clearance in 70% to 92% of cases across retrospective series, while intralesional 5-fluorouracil has achieved resolution within 3 weeks at 3 injection intervals. Radiation treatment and X-ray therapy remain relevant for older or immunocompromised patients with substantial wound-healing risk. Cryotherapy, which has shown resolution rates of 87%, can provide a lower-cost option in settings with fewer specialist resources. 

Growth of Tissue-Sparing Mohs Micrographic Surgery

The keratoacanthoma market is gaining support from the wider use of Mohs micrographic surgery in sensitive or cosmetically important anatomical locations. A 2024 comparative analysis found that keratoacanthoma required a mean of 1.28 Mohs stages, compared with 1.52 stages for invasive cutaneous squamous cell carcinoma. The study reported no keratoacanthoma recurrences at a mean follow-up of 1.5 years, supporting the procedure for lesions where margin control is important. A lower average number of stages can reduce surgical sessions and complications, while preserving tissue on the face, scalp, and acral areas. European accreditation efforts are expanding the number of credentialed Mohs surgeons and aligning practice with the European Academy of Dermatology and Venereology frameworks. This development can extend procedural capacity beyond North America into higher-income European and Asia-Pacific settings.

AI-Assisted Dermoscopy and Therapy-Associated Lesions

The keratoacanthoma market is also shaped by digital dermoscopy and a growing stream of lesions associated with cancer therapies and immunosuppression. A 2024 clinical utility study found that a digital dermoscopy image-based artificial intelligence device increased management sensitivity to 91.1% from 70.0% with unassisted assessment. Diagnostic sensitivity in the same study rose to 86.1% from 63.4%, independent of clinician training level. BRAF inhibitor monotherapy has been associated with an 8.97% keratoacanthoma incidence, compared with 1.82% for BRAF plus MEK inhibitor regimens. A review of 172 drug-induced eruptive keratoacanthoma and squamous cell carcinoma cases found that immune checkpoint inhibitor-associated lesions more often affected older patients and the lower extremities. These lesions were more often managed with oral retinoids and intralesional corticosteroids than surgical excision, creating a different mix of procedure and medication demand. 

Diagnostic Ambiguity and Regulatory Pathways

The keratoacanthoma market remains limited by the clinical and histological overlap between keratoacanthoma and well-differentiated cutaneous squamous cell carcinoma. This uncertainty encourages treatment that prioritizes complete excision and histopathologic confirmation, even when a lesion may otherwise be considered for conservative care. In the 2024 Mohs analysis, 0.8% of lesions initially managed as keratoacanthoma were upstaged during surgery to moderate or poorly differentiated cutaneous squamous cell carcinoma. Coding cases as cutaneous squamous cell carcinoma to obtain reimbursement can understate the condition-specific treatment opportunity in billing data. The same lack of clear coding and distinct clinical pathways weakens the outcome data needed for a keratoacanthoma-specific drug indication. Without an established regulatory pathway, investment in targeted drug development remains less attractive than investment in the clearer cutaneous squamous cell carcinoma indication.

Evidence, Access, and Reimbursement Constraints

The keratoacanthoma market also faces uneven access to dermatologists, reimbursement pressure, and limited high-quality evidence for non-surgical options. The American Academy of Dermatology reported a 4.7% average decline in reimbursement rates for common dermatology procedures from 2007 to 2021, and a further 2.8% Medicare physician fee cut took effect in January 2025. These conditions can discourage expansion of specialist care in rural and underserved areas where patient access is already constrained. A 2025 review described how reimbursement patterns can create disparities in dermatology care and procedure delivery. Low dermatologist-to-population ratios in parts of Asia and Sub-Saharan Africa can leave lesions in the hands of general practitioners with limited dermoscopy training. The absence of consistent, high-quality comparative evidence for non-surgical treatment also slows wider clinical adoption, particularly in emerging settings.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Solitary Presentations Dominate While Eruptive Cases Multiply

Solitary keratoacanthoma held 60.34% of the Keratoacanthoma market size in 2025, reflecting the predominance of the classic single-lesion presentation. This presentation is a rapidly growing, dome-shaped nodule with a central keratin-filled crater that commonly arises on chronically sun-exposed skin. Incidence now peaks among people aged 65 to 71 years, which aligns with ultraviolet-driven disease in older, fair-skinned populations. A single resectable lesion usually follows a direct route to excision or Mohs surgery with less diagnostic complexity. Giant keratoacanthoma, defined as a lesion larger than 2 cm, can require multistage reconstruction or radiation because local tissue destruction, challenging locations, and wound-healing risk can make primary excision insufficient.

Multiple keratoacanthoma is forecast to grow at a 6.65% CAGR through 2031, supported by therapy-associated eruptive cases at the oncology and dermatology interface. BRAF inhibitor monotherapy has been associated with keratoacanthoma in 8.97% of patients, compared with 1.82% for BRAF plus MEK inhibitor combinations. A 2025 review of 172 drug-induced eruptive keratoacanthoma and squamous cell carcinoma cases found that immune checkpoint inhibitor-associated lesions more often affected older people and the lower extremities. These cases are more often treated with oral retinoids and intralesional corticosteroids than excision, creating a different treatment revenue profile from solitary lesions. Ferguson-Smith syndrome, Grzybowski generalized eruptive keratoacanthoma, subungual keratoacanthoma, and mucosal keratoacanthoma are rare forms where lesion multiplicity, recurrence, or tissue anatomy can complicate long-term surgical care.

By Treatment and Diagnosis: Therapeutic Procedures Lead as Pharmacology Gains Pace

Therapeutic procedures held 56.38% of the treatment and diagnosis segment in 2025. Surgical procedures support this position because excision combines treatment with definitive histopathologic staging. Mohs surgery is particularly relevant in cosmetically sensitive locations and cleared keratoacanthoma in a mean of 1.3 stages in the 2024 comparative study. Cryotherapy, electrodesiccation, curettage, and photodynamic therapy offer office-based local control when speed is more important than histopathologic confirmation. Cryotherapy had resolution rates of 87% in the supplied clinical evidence base. Radiation remains important for older patients or medically complex patients who cannot undergo surgery, while diagnostic procedures such as dermoscopy and biopsy feed therapeutic volumes.

The Keratoacanthoma market size for pharmacological treatment is forecast to grow at a 7.13% CAGR through 2031. This path serves patients whose multiple or therapy-associated lesions would make surgery disproportionately burdensome. Intralesional methotrexate showed 70-92% clearance in retrospective series, while intralesional 5-fluorouracil resolved lesions in 3 weeks across 3 injection cycles. In July 2026, SKNV secured exclusive rights to a Washington University fluorouracil and calcipotriene patent portfolio for Kefunova Cream. The International Immunosuppression and Transplant Skin Cancer Collaborative had recommended the combination in April 2026 for high-risk patients, including organ transplant recipients. Oral retinoids and corticosteroids also have a distinct role in immune checkpoint inhibitor and BRAF inhibitor-associated eruptive disease.

By End User: Hospitals Anchor Volumes, Specialty Settings Build Structural Share

Hospitals accounted for 45.67% of the keratoacanthoma market revenue in 2025. Their position rests on co-located pathology, surgical suites, and multidisciplinary oncology teams. These resources are valuable for complex lesions and treatment-emergent lesions associated with checkpoint inhibitors or BRAF inhibitors. Academic centers in the United States have adopted reflectance confocal microscopy for pre-excision characterization, helping reduce diagnostic excisions while maintaining assessment for cutaneous squamous cell carcinoma differentiation. Hospitals also manage patients needing general or regional anesthesia because of comorbidities, lesion size, or high-risk anatomical sites. This service mix maintains the hospital's role in the Keratoacanthoma industry.

Dermatology clinics are the fastest-growing end-user setting, with a projected 7.89% CAGR through 2031. Mohs surgery and other procedural services are moving toward specialty settings with lower overhead than hospitals. Ambulatory surgical centers are also taking a larger role in routine excisions under fee schedules that favor outpatient care. Telemedicine pre-screening can direct patients to dermatology clinics before an excisional procedure is scheduled. Clinics with artificial intelligence-enabled dermoscopy can concentrate specialist procedural volume after a higher-confidence assessment. Medical research laboratories add revenue through molecular assays and gene expression profiling, which may support future keratoacanthoma-specific submissions and link diagnostic services with procedures.

Geography Analysis

North America held 37.83% of the keratoacanthoma market size in 2025, supported by a high density of board-certified dermatologists and Mohs surgeons. The region also has established reimbursement for lesion excision and substantial use of checkpoint inhibitors and BRAF inhibitors. The United States accounted for most regional revenue, while Canada and Mexico contributed smaller but growing volumes. Canadian provincial health systems are expanding telemedicine dermatology referrals that can route previously undetected lesions into specialist care. The American Academy of Dermatology challenged the 2.8% Medicare physician fee cut that took effect in January 2025, which indicates continued pressure on provider access. Despite this pressure, established Mohs capacity and broader artificial intelligence-assisted dermoscopy support the region’s position.

Asia-Pacific is forecast to achieve the fastest regional growth at a 8.24% CAGR through 2031. Australia and New Zealand have high age-standardized non-melanoma skin cancer incidence, supporting a sizable base for skin lesion procedures and private insurance-backed excision. China and India are expanding Mohs capacity in urban hospital dermatology departments, although rural access gaps remain. Government dermatology training programs in both countries can expand the specialist workforce needed to address latent demand. Japan’s population was more than 28% aged 65 or older, which aligns with growing clinical documentation of keratoacanthoma in older adults. South Korea’s digital health infrastructure supports faster deployment of artificial intelligence-enabled dermoscopy and may make it an early setting for new triage tools.

Europe held a significant keratoacanthoma market share in 2025, led by Germany, the United Kingdom, and France with integrated dermatology and histopathology services. The European Academy of Dermatology and Venereology is supporting Mohs accreditation expansion across member states, addressing a long-standing capacity gap with North America. Spanish clinical literature has documented intralesional methotrexate and 5-fluorouracil as treatment alternatives for facial and acral lesions in older patients. The Middle East and Africa remain at an earlier stage, with Gulf Cooperation Council countries advancing through private hospital growth and medical tourism. Brazil anchors South American demand through its urban hospital network, elevated ultraviolet exposure, and increasing immuno-oncology prescribing.